Combination of azacitidine,venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms |
| |
Authors: | Thomas Systchenko,Jean-Claude Chomel,Pilar Gallego-Hernanz,Niels Moya,Déborah Desmier,Natacha Maillard,Arthur Bobin,Mathilde Vonfeld,Hélène Gardeney,Emilie Cayssials  E,José Torregrosa |
| |
Affiliation: | 1. Haematology Department, CHU de Poitiers, Poitiers, France;2. Department of Cancer Biology, Onco-Hematology Unit, CHU de Poitiers, Poitiers, France |
| |
Abstract: | Myeloproliferative neoplasms in blastic phase (MPN-BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN-BP patients treated with a never-before-described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72–84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow-up of 10.0 months (range 4.2–13.4), median overall survival was 13.4 months (95% CI 4.2–13.4). We did not detect any unexpected treatment-related toxicity, and quality of life was improved. |
| |
Keywords: | azacitidine blast phase myeloproliferative neoplasms ruxolitinib venetoclax |
|
|